[go: up one dir, main page]

MX2019010759A - Mitorriboscinas: compuestos terapeuticos basados en mitocondrias que fijan como objetivo celulas cancerosas, bacterias y levaduras patogenas. - Google Patents

Mitorriboscinas: compuestos terapeuticos basados en mitocondrias que fijan como objetivo celulas cancerosas, bacterias y levaduras patogenas.

Info

Publication number
MX2019010759A
MX2019010759A MX2019010759A MX2019010759A MX2019010759A MX 2019010759 A MX2019010759 A MX 2019010759A MX 2019010759 A MX2019010759 A MX 2019010759A MX 2019010759 A MX2019010759 A MX 2019010759A MX 2019010759 A MX2019010759 A MX 2019010759A
Authority
MX
Mexico
Prior art keywords
mitochondrial
mitoriboscins
bacteria
cancer cells
pathogenic yeast
Prior art date
Application number
MX2019010759A
Other languages
English (en)
Other versions
MX390968B (es
Inventor
P Lisanti Michael
Sotgia Federica
Original Assignee
Lunella Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lunella Biotech Inc filed Critical Lunella Biotech Inc
Publication of MX2019010759A publication Critical patent/MX2019010759A/es
Publication of MX390968B publication Critical patent/MX390968B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/64—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms
    • C07C217/66—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms with singly-bound oxygen atoms and six-membered aromatic rings bound to the same carbon atom of the carbon chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/74—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/46—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
    • C07C275/20—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
    • C07C275/24—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D223/04—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with only hydrogen atoms, halogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
    • G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
    • G16C20/50—Molecular design, e.g. of drugs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Computing Systems (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)

Abstract

La presente descripción se refiere a inhibidores de la función mitocondrial. Se dan a conocer métodos de prospección de los compuestos para la inhibición mitocondrial. También se describen métodos para usar inhibidores mitocondriales llamados mitorriboscinas - compuestos terapéuticos basados en mitocondrias que tienen propiedades anti-cancerosas y antibióticas - para prevenir o tratar el cáncer, infecciones bacterianas y levadura patógena, así como también métodos para usar inhibidores mitocondriales para proporcionar beneficios antienvejecimiento. También se dan a conocer compuestos específicos de mitorriboscina y grupos de mitorriboscinas.
MX2019010759A 2017-03-15 2018-03-14 Mitorriboscinas: compuestos terapeuticos basados en mitocondrias que fijan como objetivo celulas cancerosas, bacterias y levaduras patogenas MX390968B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762471688P 2017-03-15 2017-03-15
PCT/US2018/022403 WO2018170109A1 (en) 2017-03-15 2018-03-14 Mitoriboscins: mitochondrial-based therapeutics targeting cancer cells, bacteria, and pathogenic yeast

Publications (2)

Publication Number Publication Date
MX2019010759A true MX2019010759A (es) 2019-12-11
MX390968B MX390968B (es) 2025-03-21

Family

ID=63523316

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2019010759A MX390968B (es) 2017-03-15 2018-03-14 Mitorriboscinas: compuestos terapeuticos basados en mitocondrias que fijan como objetivo celulas cancerosas, bacterias y levaduras patogenas
MX2022000937A MX2022000937A (es) 2017-03-15 2018-03-14 Mitorriboscinas: compuestos terapéuticos basados en mitocondrias que fijan como objetivo células cancerosas, bacterias y levaduras patógenas.
MX2022000938A MX2022000938A (es) 2017-03-15 2018-03-14 Mitorriboscinas: compuestos terapeuticos basados en mitocondrias que fijan como objetivo celulas cancerosas, bacterias y levaduras patogenas.

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2022000937A MX2022000937A (es) 2017-03-15 2018-03-14 Mitorriboscinas: compuestos terapéuticos basados en mitocondrias que fijan como objetivo células cancerosas, bacterias y levaduras patógenas.
MX2022000938A MX2022000938A (es) 2017-03-15 2018-03-14 Mitorriboscinas: compuestos terapeuticos basados en mitocondrias que fijan como objetivo celulas cancerosas, bacterias y levaduras patogenas.

Country Status (23)

Country Link
US (4) US11311501B2 (es)
EP (1) EP3596043B1 (es)
JP (2) JP7104134B2 (es)
KR (1) KR102623283B1 (es)
CN (1) CN110621655B (es)
AU (2) AU2018235937A1 (es)
BR (1) BR112019019109B1 (es)
CA (1) CA3056086A1 (es)
CL (1) CL2019002580A1 (es)
CO (1) CO2019010027A2 (es)
CR (2) CR20190458A (es)
CU (3) CU20190096A7 (es)
DO (3) DOP2019000230A (es)
EC (1) ECSP19073204A (es)
IL (2) IL305316B2 (es)
MX (3) MX390968B (es)
NZ (1) NZ756854A (es)
PE (1) PE20191485A1 (es)
PH (1) PH12019502056B1 (es)
RU (1) RU2019132396A (es)
SG (1) SG11201908487YA (es)
WO (1) WO2018170109A1 (es)
ZA (5) ZA201905970B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2744989B2 (ja) 1992-07-24 1998-04-28 光洋機械工業株式会社 小径工作物の外径寸法測定システム
US20220339125A1 (en) * 2017-03-15 2022-10-27 Lunella Biotech, Inc. Mitoriboscins: mitochondrial-based therapeutics targeting cancer cells, bacteria, and pathogenic yeast
WO2019075219A1 (en) 2017-10-11 2019-04-18 Lunella Biotech, Inc. ANTIMITOCHONDRIAL INHIBITORS FOR ONCOGENES RAS AND MYC
US12188936B2 (en) 2018-06-01 2025-01-07 Lunella Biotech, Inc. Biomarkers and therapeutics for endocrine therapy resistance
KR20210072026A (ko) 2018-10-02 2021-06-16 루넬라 바이오테크 인코포레이티드 세놀리틱 약물로서 아지트로마이신 및 록시스로마이신 유도체
KR20210104830A (ko) * 2018-12-17 2021-08-25 루넬라 바이오테크 인코포레이티드 항노화를 위한 삼중 조합 요법
BR112021011963A2 (pt) * 2018-12-17 2021-09-08 Lunella Biotech, Inc. Terapias de combinação tripla para alvejamento de mitocôndria e exterminação de células-tronco de câncer
WO2020214754A1 (en) * 2019-04-16 2020-10-22 Lunella Biotech, Inc. Alkyl-tpp compounds for mitochondria targeting and anti-cancer treatments
EP3976197B1 (en) 2019-05-24 2025-07-16 Lunella Biotech, Inc. Therapeutics and methods for predicting and overcoming endocrine resistance in breast cancer
EP4139484A4 (en) 2020-04-24 2024-08-28 Lunella Biotech, Inc. THERAPEUTIC METHODS FOR THE PREVENTION OF TUMOR METASTASES AND RECURRENCES

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2062025A (en) * 1931-12-19 1936-11-24 Harrington Joseph Method and apparatus for treating moisture-containing substances
US2059764A (en) * 1933-11-03 1936-11-03 Zerillo Frank Pneumatic tire
US2058655A (en) * 1934-10-12 1936-10-27 Borg Warner Friction clutch
JPS537424B2 (es) 1971-10-08 1978-03-17
US5756507A (en) 1995-12-14 1998-05-26 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
JP2000001433A (ja) 1998-06-11 2000-01-07 Pfizer Pharmaceuticals Inc ５―リポキシゲナ―ゼ阻害剤
GB0323585D0 (en) * 2003-10-08 2003-11-12 Glaxo Group Ltd Compounds
KR101274524B1 (ko) 2004-03-16 2013-06-19 온코노바 테라퓨틱스, 인코포레이티드 증식성 질병 치료용 치환 페녹시- 및 페닐티오- 유도체
JP4330169B2 (ja) * 2004-11-29 2009-09-16 国立大学法人名古屋大学 グリコペプチド抗生物質モノマー誘導体
BRPI0710559A2 (pt) * 2006-04-21 2011-08-16 Smithkline Beecham Corp antagonistas de receptores de il-8
CL2008000725A1 (es) * 2007-03-15 2008-11-14 Schering Corp Compuestos derivados de heterociclos aromaticos; composicion farmaceutica; kit farmceuticos; uso de la composicion y de los compuestos como inhibidores de glucano sintasa para el tratamiento o prevencion del crecimiento de patogenos fungicos en planta y para tratar o prevenir infecciones producidas por hongos.
FR2932483A1 (fr) 2008-06-13 2009-12-18 Cytomics Systems Composes utiles pour le traitement des cancers.
SI2391363T1 (sl) * 2009-01-29 2017-01-31 Young Hee Ko Sestavki in postopki za zdravljenje raka
EP2433133A2 (en) * 2009-05-20 2012-03-28 Universite De Geneve Mitochondrial activity inhibitors of cancer-initiating cells and use thereof
AU2011283684B2 (en) 2010-07-29 2015-08-27 Rigel Pharmaceuticals, Inc. AMPK-activating heterocyclic compounds and methods for using the same
US20140288077A1 (en) 2011-07-05 2014-09-25 St. Jude Children's Research Hospital Substituted 4-phenoxyphenol analogs as modulators of proliferating cell nuclear antigen activity
CN102886054B (zh) * 2011-07-19 2014-04-02 复旦大学 一种抑制细菌信号转导系统PhoQ组氨酸激酶活性的制剂
KR102205202B1 (ko) * 2013-02-01 2021-01-21 웰스태트 테러퓨틱스 코포레이션 항염증, 항진균, 항기생충, 및 항암 활성을 갖는 아민 화합물
CA2884607A1 (en) * 2015-03-11 2016-09-11 Stealth Peptides International, Inc. Therapeutic compositions including acrylamido compounds or phenyl-substiituted maleimide compounds and uses thereof to treat and prevent mitochondrial diseases and conditions

Also Published As

Publication number Publication date
AU2022205218A1 (en) 2022-08-04
IL305316B2 (en) 2024-09-01
EP3596043A1 (en) 2020-01-22
DOP2022000164A (es) 2022-11-30
IL269309B1 (en) 2023-09-01
EP3596043B1 (en) 2025-12-03
KR20190130595A (ko) 2019-11-22
US10512618B2 (en) 2019-12-24
KR102623283B1 (ko) 2024-01-11
MX2022000937A (es) 2022-10-21
CR20220381A (es) 2022-09-15
MX390968B (es) 2025-03-21
ZA202203603B (en) 2023-12-20
IL305316B1 (en) 2024-05-01
PE20191485A1 (es) 2019-10-18
DOP2022000165A (es) 2022-11-30
MX2022000938A (es) 2022-12-14
AU2018235937A1 (en) 2019-09-19
WO2018170109A1 (en) 2018-09-20
RU2019132396A3 (es) 2021-04-15
DOP2019000230A (es) 2020-01-31
US20210186898A9 (en) 2021-06-24
PH12019502056B1 (en) 2024-04-17
CU20190097A7 (es) 2020-10-20
ZA202101517B (en) 2023-01-25
ECSP19073204A (es) 2019-10-31
US20190091181A1 (en) 2019-03-28
JP7104134B2 (ja) 2022-07-20
SG11201908487YA (en) 2019-10-30
IL305316A (en) 2023-10-01
JP2020514418A (ja) 2020-05-21
BR112019019109A2 (pt) 2020-04-22
ZA202001040B (en) 2021-08-25
US11311501B2 (en) 2022-04-26
CN110621655B (zh) 2023-03-10
CR20190458A (es) 2019-12-18
RU2019132396A (ru) 2021-04-15
US20200170967A1 (en) 2020-06-04
US11364210B2 (en) 2022-06-21
CO2019010027A2 (es) 2019-09-30
US20210130370A1 (en) 2021-05-06
NZ756854A (en) 2022-02-25
CU20190096A7 (es) 2020-10-20
US20200060998A1 (en) 2020-02-27
BR112019019109B1 (pt) 2023-11-07
ZA201905970B (en) 2021-01-27
JP7312891B2 (ja) 2023-07-21
IL269309B2 (en) 2024-01-01
IL269309A (en) 2019-11-28
AU2022205218B2 (en) 2023-11-23
JP2022133418A (ja) 2022-09-13
US11547679B2 (en) 2023-01-10
PH12019502056A1 (en) 2020-07-06
CU20190079A7 (es) 2020-04-02
CN110621655A (zh) 2019-12-27
CL2019002580A1 (es) 2020-02-14
CA3056086A1 (en) 2018-09-20
ZA202001041B (en) 2021-10-27

Similar Documents

Publication Publication Date Title
DOP2022000165A (es) MITORRIBOSCINAS: COMPUESTOS TERAPÉUTICOS BASADOS EN MITOCONDRIAS QUE FIJAN COMO OBJETIVO CÉLULAS CANCEROSAS, BACTERIAS y LEVADURAS PATÓGENAS
CO2018009275A2 (es) Derivados pirrolidina espiro-condensados como inhibidores de enzimas desubiquitinantes (dub)
CO2019011543A2 (es) Inhibidores de pd-1/pd-l1
BR112017024384A2 (pt) bactérias modificadas para reduzir hiperfenilalaninemia
CL2018001685A1 (es) Compuestos heterociclicos como inmuno moduladores.
CR20190318A (es) Compuestos heterocíclicos como inmunomoduladores
MX2016009898A (es) Tratamientos para acne resistente.
MX2020004211A (es) Mitoflavoscinas: la fijacion como objetivo de enzimas que contienen flavina elimina celulas madre cancerosas (cscs) al inhibir la respiracion mitocondrial.
MX2018010993A (es) Derivados de icariina e icaritina.
DOP2022000142A (es) Mitocetoscinas: agentes terapéuticos basados en mitocondrias que fijan como objetivo el metabolismo de cetonas en células cancerosas
MX2022012013A (es) Composiciones y metodos para transduccion de tumores.
DOP2019000019A (es) Metodos para tratar el cancer de prostata
PH12016501988A1 (en) Antibacterial compounds
CY1122403T1 (el) Μορφες δοσολογιας και θεραπευτικες χρησεις της l-4-χλωροκυνουρενινης
EA201590656A1 (ru) Азаиндолины
MX2018007158A (es) Uso de compuestos fenolicos derivados de arandano como agente sinergizante antibiotico contra bacterias patogenicas.
BR112017021114A8 (pt) Compostos heterocíclicos como inibidores de lsd1